Request Trial
shutterstock-101016205-toria-shutterstock-com
Toria / Shutterstock.com
7 October 2016Big Pharma

Event preview: Life Sciences Patents Network Europe 2016

Newton Media, the publisher of Life Sciences IP Review, is excited to host this publication’s first event. On December 7, 2016, the best and brightest people working in life sciences intellectual property, including in-house counsel and private practitioners, will converge on the Bloomsbury Hotel in London for a day of networking, education and debate.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
Report reveals surge of AI adoption in IP but lawyers remain cautious
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
Big Pharma
Sun Pharma and BMS lead 2025 ANDA litigation
10 November 2025   According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.


Editor's picks

The quantum advantage: IP considerations for the next generation of life sciences innovation
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

Editor's picks

Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025

More features

Moderna VP and regulatory expert moves to private practice
Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger
Sanofi suffers setback in insulin monopoly dispute
Eli Lilly’s Mounjaro tops list of cyber squatter targets
The quantum advantage: IP considerations for the next generation of life sciences innovation
Fed Circ overturns PTAB decision in $83.4m DNA case
AI is transforming top 100 innovators, shows index
Novartis win blocks generics relitigating $7.8bn heart drug patent